FIKES et al.

Application No.: 09/458,297

Page 4

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 321, at the end of the application.

REMARKS

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-1490, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "FastSEQ" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor

San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

JML:dmw

FIKES et al.

Application No.: 09/458,297

Page 5

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 3 of page 51 has been amended as follows:

In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majority of the population. This can be accomplished by selecting amino acid sequences that bind to many, most, or all of the HLA class II molecules. These are known as "loosely HLA-restricted" or "promiscuous" T helper sequences. Examples of amino acid sequences that are promiscuous include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO:1487), Plasmodium falciparum CS protein at positions 378-398 (DIEKKIAKMEKASSVFNVVNS; SEQ ID NO:1488), and Streptococcus 18kD protein at positions 116 (GAVDSILGGVATYGAA; SEQ ID NO:1489). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.

Paragraph beginning at line 12 of page 51 has been amended as follows:

Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (*see*, *e.g.*, PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (*e.g.*, PADRE™, Epimmune, Inc., San Diego, CA) are designed to most preferrably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVWANTLKAAa (SEQ ID NO:1490), where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless

FIKES *et al.*Application No.: 09/458,297

Page 6

of their HLA type. An alternative of a pan-DR binding epitope comprises all "L" natural amino acids and can be provided in the form of nucleic acids that encode the epitope.

SF 1304343 v1